The Latest Cardiac and Vascular News
SAN FRANCISCO, Oct. 29, 2020 (GLOBE NEWSWIRE) — Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today reported its financial results for the third quarter ended September 30, 2020 and provided an update on the company’s operations. “The completion of enrollment in our […]
SAN FRANCISCO, Oct. 05, 2018 (GLOBE NEWSWIRE) — Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today announced that results of its Phase 2 clinical trial studying AG10 in subjects with symptomatic transthyretin (TTR) amyloidosis cardiomyopathy (ATTR-CM) will be announced in a late-breaking […]
SAN FRANCISCO, May 3, 2018 /PRNewswire/ — Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company developing a novel oral therapy to treat transthyretin (TTR) amyloidosis (ATTR), today announced dosing of the first patient in the Phase 2 clinical trial of AG10 in patients […]
